SI T027
Alternative Names: SI-T027Latest Information Update: 28 May 2023
At a glance
- Originator Sichuan Baili Pharmaceutical
- Developer Sichuan Baili Pharmaceutical; SystImmune
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer; Solid tumours
Most Recent Events
- 28 May 2023 No recent reports of development identified for research development in Liver-cancer in China (Parenteral)
- 28 May 2023 No recent reports of development identified for research development in Liver-cancer in USA (Parenteral)
- 28 May 2023 No recent reports of development identified for research development in Solid-tumours in China (Parenteral)